Literature DB >> 21152987

Functional characterization of promoter region polymorphisms of human CYP2C19 gene.

Uppugunduri Satyanarayana Chakradhara Rao1, Anichavezhi Devendran, Kapettu Satyamoorthy, Deepak Gopal Shewade, Rajgopal Krishnamoorthy, Adithan Chandrasekaran.   

Abstract

CYP2C19 is an enzyme involved in the metabolism of several clinically important drugs. The variations in the CYP2C19 promoter region may alter the transcription of the gene by altering the interaction between the trans and cis-acting elements. In the present study, CYP2C19 promoter region with different variant alleles were cloned into a pGL-3 basic luciferase reporter vector and transfected into HepG2 cell lines. Subsequently, dual luciferase activity was measured to evaluate the activity of the promoter region. Gel shift assays with predicted binding sites for CCAAT displacement protein, activating transcription factor-2 and glucocorticoid receptor were performed. Results from this study indicate that few variations present in the putative cis-acting elements of the CYP2C19 promoter region such as -1442T>C, -779A>C and -98T>C -1498T>G and -828del>T alter the transcription of the gene. Specific binding with nuclear proteins was also observed in gel shift assays. This may account for the interindividual variations in gene expression and genotype dependant differences in gene transcription. The results also suggest the role of activating transcription factor-2 and CCAAT displacement repressor protein on CYP2C19 gene transcription.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21152987     DOI: 10.1007/s11033-010-0537-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  22 in total

1.  Genetic variations and haplotypes of the 5' regulatory region of CYP2C19 in South Indian population.

Authors:  Chakradhara Rao Uppugunduri Satyanarayana; Anichavezhi Devendran; Rajan Sundaram; Shewade Deepak Gopal; Krishnamoorthy Rajagopal; Adithan Chandrasekaran
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

2.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

3.  Influence of the genetic polymorphisms in the 5' flanking and exonic regions of CYP2C19 on proguanil oxidation.

Authors:  Chakradhara Rao Uppugunduri Satyanarayana; Anichavezhi Devendran; Muthukumaran Jayaraman; Jayakanthan Mannu; Premendu P Mathur; Shewade Deepak Gopal; Krishnamoorthy Rajagopal; Adithan Chandrasekaran
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

4.  ATF-2 and C/EBPalpha can form a heterodimeric DNA binding complex in vitro. Functional implications for transcriptional regulation.

Authors:  J D Shuman; J Cheong; J E Coligan
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

5.  Transcriptional regulation of the cholesterol side chain cleavage cytochrome P450 gene (CYP11A1) revisited: binding of GATA, cyclic adenosine 3',5'-monophosphate response element-binding protein and activating protein (AP)-1 proteins to a distal novel cluster of cis-regulatory elements potentiates AP-2 and steroidogenic factor-1-dependent gene expression in the rodent placenta and ovary.

Authors:  Noa Sher; Natalie Yivgi-Ohana; Joseph Orly
Journal:  Mol Endocrinol       Date:  2007-01-09

6.  The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.

Authors:  H J Feng; S L Huang; W Wang; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes.

Authors:  Judy L Raucy; Lisa Mueller; Kui Duan; Scott W Allen; Stephen Strom; Jerome M Lasker
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

Review 9.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

Authors:  Magnus Ingelman-Sundberg; Sarah C Sim; Alvin Gomez; Cristina Rodriguez-Antona
Journal:  Pharmacol Ther       Date:  2007-10-09       Impact factor: 12.310

10.  Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.

Authors:  Janelle M Hoskins; Gillian M Shenfield; Annette S Gross
Journal:  Eur J Clin Pharmacol       Date:  2003-09-12       Impact factor: 2.953

View more
  4 in total

1.  Regulatory polymorphisms in CYP2C19 affecting hepatic expression.

Authors:  Jonathan C Sanford; Yingying Guo; Wolfgang Sadee; Danxin Wang
Journal:  Drug Metabol Drug Interact       Date:  2013

2.  Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.

Authors:  Mirjana Novkovic; Dragan Matic; Jelena Kusic-Tisma; Nebojsa Antonijevic; Dragica Radojkovic; Ljiljana Rakicevic
Journal:  Eur J Clin Pharmacol       Date:  2017-12-19       Impact factor: 2.953

3.  Haplotypes in the promoter region of the CIDEC gene associated with growth traits in Nanyang cattle.

Authors:  Jing Wang; Liu-shuai Hua; Hong Pan; Liang-zhi Zhang; Ming-xun Li; Yong-zhen Huang; Zhuan-jian Li; Xian-yong Lan; Chu-zhao Lei; Cong-jun Li; Hong Chen
Journal:  Sci Rep       Date:  2015-07-20       Impact factor: 4.379

4.  Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.

Authors:  Nuala Ann Helsby; Kathryn Elisa Burns
Journal:  Front Genet       Date:  2012-10-10       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.